Oxaliplatin Teva (Oxaliplatin)

Oxaliplatin creates platinum‑DNA adducts that cause intra‑ and interstrand cross‑links, blocking DNA replication and transcription. This DNA damage triggers programmed cell death (apoptosis) in rapidly dividing tumour cells, limiting tumour growth.

The prescribed dose of Oxaliplatin Teva is determined by the treating oncologist based on the patient’s body surface area, cancer type, and treatment protocol. Exact dosing regimens are individualized and should follow the relevant clinical guidelines.

Oxaliplatin is classified as contraindicated in pregnancy because it may cause fetal harm. It is also not recommended while breastfeeding, as it can be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Oxaliplatin differs from cisplatin and carboplatin in its side‑effect profile, showing less nephrotoxicity and ototoxicity but a higher incidence of peripheral neuropathy. Its efficacy in colorectal cancer is superior, making it the preferred platinum agent in many modern regimens.

Oxaliplatin Teva should be stored below 25 °C in its original packaging, protected from light and moisture. The solution must be prepared in a sterile environment and used promptly after reconstitution according to the product’s stability guidelines.

Oxaliplatin Teva is given as an intravenous infusion, typically over 2 hours, under the supervision of an oncology specialist. Infusion rates and pre‑hydration protocols are adjusted according to the patient’s renal function and overall health status.

Serious risks include severe peripheral neuropathy that may become permanent, acute hypersensitivity reactions, and significant bone‑marrow suppression leading to pancytopenia. Prompt monitoring and supportive care are essential to manage these potential complications.

Patients with known hypersensitivity to oxaliplatin or other platinum compounds, severe pre‑existing neuropathy, uncontrolled renal or hepatic impairment, and pregnant or breastfeeding women should not receive this medication.